<DOC>
	<DOCNO>NCT02342054</DOCNO>
	<brief_summary>High-dose rate brachytherapy ( HDR-BT ) advance technology theorize advantageous LDR-BT External Beam Radiotherapy ( EBRT ) , patient , term resource allocation . Studies HDR-BT monotherapy encourage result term biochemical control , patient survival toxicity , still certain limitation preclude recommend HDR-BT monotherapy outside set clinical trial . The primary endpoint study evaluate safety , tolerance impact quality life ( QoL ) BT-HDR 19Gy administer single fraction patient low intermediate risk prostate cancer . Secondary endpoint measure efficacy , term cancer control satisfaction patient undergoing experimental treatment . Forty nine patient recruit experimental procedure Quality Life , tolerance , gastrointestinal genitourinary toxicity assess use standardized procedure scale . Patient satisfaction procedure appraise use five-category predetermined Likert scale question . Two different type intermediate analysis perform : 15 30 recruited patient . The experimental treatment test study innovative . Since prostate cancer frequent cancer men Spain , trial result likely major impact standard therapy prostate cancer National Health Service , allow high number Hospitals within country country start protocol HDR BT 19Gy single fraction .</brief_summary>
	<brief_title>Single Fraction Real-time High-Dose-Rate Brachytherapy Patients With Low Intermediate Risk Prostate Cancer</brief_title>
	<detailed_description>Treatment : The patientÂ´s treatment consist MRI-TRUS fusion single HDR brachytherapy fraction ( 1 fraction 1900 cGray ) . Brachytherapy perform general anesthesia outpatient procedure TRUS-MRI fusion : T2 axial volumetric sequence ( VISTA ) import directly picture archive communication system ( PACS ) . Then MR image reconstruct segment . Target volume ( prostate gland , dominant intraprostatic lesion ( DILs ) Organs risk ( OARs ) urethra rectum delineate . A transrectal sagittal volumetric ultrasound image immediately acquire every 2 degree , rapid reconstruction algorithm convert series 2D image 3D volume , displayed axial , sagittal coronal view transfer module fusion MRI . The MRI image real-time sonography examination display split-screen possibility overlay image live one image . A graphical user interface use rigid manual registration ultrasound MRI volume . This interface allow displacement three dimension rotation , image correctly superimpose . Then contour structure transfer US dataset , contour slightly modify perfect match US image achieve . Dose prescription : Ultrasound image catheter place export Oncentra Prostate . The prostate , Foley catheter anterior rectal wall contour . Catheters reconstruct plan system . Anatomy base inverse planning use dwell time optimization . The homogeneity parameter use optimization aim : -For prostate V100 &gt; 95 % , V150 &lt; 35 % , V200 &lt; 6 % , Vn fractional volume organ receive n % prescribe dose . The dose constraint organ risk : - Urethral dmax &lt; 110 % - Rectal 1cc &lt; 60 % prescribe dose . Endpoints Feasibility high dose administration , toxicity efficacy measure</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Men old 18 year old Histologically confirm diagnosis adenocarcinoma prostate Clinical stage T1c/T2a disease Low Intermediate risk disease define either Gleason 6 Gleason 7 PSA &lt; 20 ng/ml . Prostate volume &lt; 60 cc determine ultrasound , CT MRI Life expectancy 10 year Willing give inform consent participate clinical trial Able willing complete Expanded Prostate Index Composite ( EPIC ) questionnaire Eastern Cooperative Oncology Group ( ECOG ) 0 2 . Give competent inform consent participate trial . Documented nodal distant metastases Previous pelvic radiotherapy Previous transurethral resection prostate , previous prostatectomy HIFU Use androgen deprivation therapy . Use 5alphareductase inhibitor permit Poor baseline urinary function define International Prostate Symptom Score ( IPSS ) &gt; 19 Contraindication radical prostate radiotherapy Significant medical comorbidity render patient unsuitable general anaesthetic</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Brachytherapy</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>High Dose Rate</keyword>
	<keyword>MRI-TRUS fusion</keyword>
	<keyword>Detection DILs MRI</keyword>
	<keyword>SINGLE FRACTION</keyword>
</DOC>